Clinical trials are pivotal in advancing medical research and developing cutting-edge treatments. They serve as a vital bridge between scientific innovation and patient care, allowing for evaluating new therapies, medicines, and medical devices.
Erica Cohen, Greenphire, and Thomas Smith, LS public engagement specialist, explore the current issues that hinder rare disease clinical trials, and what solutions should be invested and incorporated to maximise flexibility for the trial patients.
Editor, Rebekah Jordan, sat down with Dr. Gen Li, president and co-founder of Phesi, to learn more about how the company’s AI-driven clinical database is allowing insights and observations to be drawn from big clinical trial data.
Matthew Lowrie, quality assurance manager, Almac Clinical Technologies explores how the evolving regulatory guidance around data integrity is impacting clinical trial applications and data.
Zabir Macci, director of eCOA business strategy & sales engineering at IQVIA, describes how to navigate global regulatory guidance for successful multinational clinical trials.
Bruno Speder, VP of regulatory affairs & consultancy services, hVIVO, discusses how Human Challenge Trials (HCT) can be used in the framework of expedited review programs as part of drug and vaccine development.
Stefan Duerr, sr. director, head of the Cenduit Drug Supply Center of Excellence, and IQVIA business, explains how a flexible and innovative approach to Interactive Response Technology (IRT) can help navigate today's clinical trial landscape.
Shauna Aherne, president of Med Evoke, shares her insights on the challenges that remain in rare disease clinical development, and what changes need to incur in clinical trials to bridge the rare disease treatment gap.
Barbara Arone, vice president, real world solutions, IQVIA, examines the ways biotech and emerging biopharma companies can effectively apply real world evidence (RWE) early in the product lifecycle while staying within their resource limits.
A recent panel debate moderated by Christian K. Schneider, head of Biopharma Excellence, explored emerging approaches to clinical research and data collection for therapies linked to rare diseases.
Natalie DiMambro, VP product commercialisation and training, Within3, explores the technologies and trends that are causing leaders to redefine current practices and invest more heavily in innovation to stay ahead of the curve in 2023.
